HarmonyFidelisHarmonyFidelis
Login
NewsMajor ProjectsActorsAcademy
Back to actors

Actor profile / Laboratory

Calico

Calico Life Sciences LLC

Mission : Harness advanced technologies to increase human healthspan.

AboutSources & documents

AI-generated conceptual illustration of the field; not a photograph of this actor or its facilities.

Founded
2013
Headquarters
San Francisco, California, USA
Status
Active

Research & methods

Laboratoire de recherche du vieillissement. Drug discovery, biomarkers, cellular reprogramming, aging biology.

Research areas

  • Aging biology
  • Drug discovery
  • Senolytics
  • Cellular reprogramming
  • Biomarkers

Development & current work

These earlier milestones have no linked primary evidence. They need verification and are not confirmed commitments.
  • 2025 · ABBV-CLS-628 enters Phase 2 for ADPKD

    Calico reported on 2 October 2025 that its anti-PAPP-A monoclonal antibody had received FDA Fast Track designation and was enrolling an ongoing Phase 2 trial for autosomal dominant polycystic kidney disease. It is not described as a senolytic.

  • 2026 · Combination therapy trials initiate

    Multiple senolytic agents + reprogramming regimen.

  • 2028 · Age reversal demonstrated 5+ years

    Biomarker validation. Aging reversal in humans.

Ecosystem participation

Longevity & Anti-Aging

Organisation & documentary record

Legal identity

Legal name
Calico Life Sciences LLC
Status
Active
Verified on
2026-08-30
Review due
2026-11-30
Calico Life Sciences LLC

Sources & documents

References are attached to the claims they support. Institutional documents describe the author’s own work; they do not constitute independent validation.

  1. 01

    Official organization website

    Calico Life Sciences LLC

    Verified on 2026-08-30

  2. 02

    Research

    www.calicolabs.com